Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Yum! Brands, Inc. — how do they compare? Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B), while Yum! Brands, Inc. trades at $148 (market cap $40.62B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3× Yum! Brands, Inc.'s market cap, and Yum! Brands, Inc. pays a 2.04% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | YUM | |
|---|---|---|
Market Cap | $121.95B | $40.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $529.59 | $168.16 |
52-Week Low | $366.54 | $138.21 |
Enterprise Value | $116.69B | $51.88B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
YUM trades at $147.10, down 0.55% amid a cyclosporiasis outbreak linked to Taco Bell lettuce. Technicals are bearish with key support at $145, while fundamentals show steady revenue growth to $8.21B in 2025 and a net margin of 20.48%. The company maintains strong cash flow from operations of $2.01B but carries high long-term debt of $11.25B.
Despite near-term headwinds from food safety concerns, YUM's diversified brand portfolio and consistent profitability support a positive long-term outlook. Analyst consensus price target of $177 suggests 20% upside, but investors should monitor outbreak resolution and Q2 2026 earnings due soon.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
